Clinical Report: Association of Nerve Conduction Velocity Patterns with CIPN Severity

Overview

This study investigates the relationship between nerve conduction study (NCS) changes and clinical severity in chemotherapy-induced peripheral neuropathy (CIPN). It identifies sural sensory nerve action potential (SNAP) amplitude as a significant predictor of CIPN severity and treatment tolerance.

Background

Chemotherapy-induced peripheral neuropathy (CIPN) is a prevalent and debilitating side effect of neurotoxic chemotherapy, affecting a substantial proportion of cancer patients. The condition can severely impact quality of life and may lead to treatment modifications or discontinuation. Understanding the relationship between NCS changes and clinical severity is crucial for improving patient management and outcomes.

Data Highlights

Key Findings

• Sural SNAP amplitude shows a strong inverse correlation with CIPN severity (r = −0.724, P < 0.001).
• Absolute end-of-treatment sural SNAP amplitude has an AUC of 0.856 for identifying Grade ≥2 CIPN.
• A relative decline in sural SNAP amplitude of ≥35% yields an AUC of 0.872.
• Patients needing dose modifications exhibit larger early reductions in sural SNAP amplitude compared to those without treatment changes.
• Four distinct electrophysiological phenotypes were identified, correlating with varying clinical severity and recovery trajectories.

Clinical Implications

The findings support the use of serial large-fiber NCS, particularly sural SNAP amplitude, as objective measures of CIPN severity. Clinicians should consider incorporating these assessments into routine practice to enhance monitoring and management of CIPN in patients undergoing neurotoxic chemotherapy.

Conclusion

This study underscores the importance of NCS in evaluating CIPN severity and treatment tolerance, providing a basis for improved patient care strategies. Further validation of these findings could enhance clinical decision-making in oncology.

Related Resources & Content

1. D’Souza et al, Regional Anesthesia & Pain Medicine, 2025 -- Chemotherapy Linked to Chronic Neuropathy for 4 in Every 10 Patients: Global Analysis Results
2. Pain Medicine, 2025 -- Tailored Outcomes in Neuropathic Pain: An Analysis of Clinical Significance and Assay Sensitivity from a Randomized Controlled Trial
3. Trivedi et al, The ASCO Post, 2023 -- Chemotherapy-Induced Peripheral Neuropathy May Be More Severe With Paclitaxel Than With Docetaxel
4. ASCO, Journal of Clinical Oncology -- Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update
5. The ASCO Post — Guidelines for Chemotherapy-Induced Neuropathy: The Known Unknowns
6. Efficacy of Hand Cooling and Compression in Preventing Taxane-Induced Neuropathy
7. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO–EONS–EANO Clinical Practice Guidelines
8. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update | Journal of Clinical Oncology